课题基金 / 基金详情

Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma

Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma
针对转移性骨肉瘤中 ERK-AKT 介导的单细胞药物反应异质性
批准号:
10283653
负责人:
Alexander E Davies
金额:
$11.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-05 至 2026-06-30

项目摘要

项目成果

Alexander E Davies的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ ABSTRACT Cellular plasticity, the ability of cells to bi-directionally transition between states over time, provides a non- genetic mechanism for cells to sample different phenotypes, spontaneously, or in response to cues from the microenvironment. In the context of cancer drug response, plasticity is problematic because it allows cancer cells to transition between drug resistant and sensitive states over time. While this phenomenon is well documented in primary tumors it appears to be a substantial problem in the metastatic microenvironment where cancer cells often exhibit profound drug resistance leading to patient mortality. In the proposed work, we aim to address this problem to determine how signals arising from the metastatic microenvironment of the lung regulate drug response plasticity and how we can inhibit phenotypic transitions from drug sensitive to resistant states in single cells. Additionally, completion of the aims proposed in this K01 submission will facilitate development of a research program that is distinct from my post-doctoral mentors, sharpen my research skills, and set the stage for a successful independent career using live-cell imaging techniques to study metastatic tumor biology and drug resistance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma
  • 批准号:
    10445087
  • 项目类别:
  • 资助金额:
    $11.97万
  • 财政年份:
    2021
  • 负责人:
    Alexander E Davies
  • 依托单位:
Targeting ERK-AKT-mediated single-cell drug response heterogeneity in metastatic osteosarcoma